Making sense of genetic testing for heart disease

26 Apr 2014

1

A new study by academics at The University of Nottingham looks at how patients respond to genetic testing for risk of coronary heart disease (CHD).

Making sense of genetic testing for heart disease

CHD is the top cause of death globally and is predicted to remain the single leading cause of death. General practitioners currently identify patients with an increased risk of the illness using conventional cardiovascular risk assessment tools that take account of risk factors, such as, blood pressure, cholesterol level, smoking and family history.

A new study – 'Introducing genetic testing for cardiovascular disease in primary care' - published in the British Journal of General Practice and led by Professor Nadeem Qureshi, from the Division of Primary Care at The University of Nottingham, explores how patients perceive the results of genetic testing, when offered the test after a conventional cardiovascular risk assessment.
 
Professor Qureshi says, ''The main reason for genetic testing for the risk of CHD is a family history of this disease, and people undergoing testing are often motivated by a desire to convey results to their children. Predictive genetic tests are currently available over the counter, but both the public and clinicians do not really understand the test results.''

Participants in the study had to deal with the complexity of conflicting findings from the genetic test, family history and conventional cardiovascular risk assessment. Ways of dealing with this included either focussing on the genetic risk or the environmental lifestyle risk factors, whilst other participants were sceptical about the value of the genetic test results.

In some participants the genetic test results helped them maintain a healthy lifestyle while others were falsely reassured by the average genetic risk result, despite having an above-average conventional cardiovascular risk assessment score.

Professor Qureshi adds, ''With this type of test being offered commercially direct to the public, general practitioners are increasingly exposed to genetic test results. They need to have an understanding of the complexity and relevance of these test results. This will be particularly challenging when the genetic test result is not consistent with CHD risk identified through conventional cardiovascular risk assessment and the family history. The results need to be presented in a clearer way, to enable the patients to take account of all of the assessments and test results. This is important to ensure that the patient maintains a healthy lifestyle.''

Latest articles

Musk ramps up SpaceX moon plans as Bezos accelerates Blue Origin in race against China

Musk ramps up SpaceX moon plans as Bezos accelerates Blue Origin in race against China

Indians can now travel to 56 destinations without prior visa as passport ranking improves

Indians can now travel to 56 destinations without prior visa as passport ranking improves

CEO says EU’s IRIS2 must match Starlink on price and performance

CEO says EU’s IRIS2 must match Starlink on price and performance

Applied Materials jumps 12% as AI chip demand drives strong revenue forecast

Applied Materials jumps 12% as AI chip demand drives strong revenue forecast

Opening the silos: India approves 3 million tonnes of wheat and product exports

Opening the silos: India approves 3 million tonnes of wheat and product exports

Capgemini beats 2025 revenue target as WNS acquisition boosts AI-driven growth

Capgemini beats 2025 revenue target as WNS acquisition boosts AI-driven growth

The deregulation “holy grail”: Trump EPA dismantles the legal bedrock of climate policy

The deregulation “holy grail”: Trump EPA dismantles the legal bedrock of climate policy

France-backed Eutelsat beats revenue estimates as Starlink rivalry intensifies

France-backed Eutelsat beats revenue estimates as Starlink rivalry intensifies

Germany’s Stark reportedly crosses €1 billion valuation after fresh funding round

Germany’s Stark reportedly crosses €1 billion valuation after fresh funding round